NCT02093169View on ClinicalTrials.gov

D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

June 30, 2014

Conditions

Healthy Men

Interventions

DRUG

Part A: Lu AF35700

One 30 mg single dose for one day; orally

DRUG

Part B: Lu AF35700

Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally

Trial Locations (1)

NW10 7EW

GB801, London

All Listed Sponsors

lead

H. Lundbeck A/S

INDUSTRY

NCT02093169 - D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound | Biotech Hunter | Biotech Hunter